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A b s t r a c t: Alkaptonuria (AKU) is a disorder of phenylalanine/tyrosine meta-
bolism due to a defect in the enzyme homogentisate 1,2-dioxygenase (HGD). This re-
cessive disease is caused by mutations in the HGD gene. We report a 14-year-old girl 
who was referred after presenting black urine. Careful examination revealed ochronosis 
of the conjunctiva. There was no affection of the cardiac valves. Elevated excretion of 
homogentisic acid in urine was found. Sequence analysis of the HGD gene from 
genomic DNA revealed that the patient is a compound heterozygote with a previously 
described mutation (c.473C > T, p.Pro158Leu), and a novel one (c.821C > T, p.Pro274Leu). 
Her mother is heterozygous for the novel mutation, while the brother is heterozygous 
for the previously described mutation. In summary, we describe an alkaptonuric patient 
with ocular ochronosis and a novel HGD mutation, c.821C > T, p.Pro274Leu. 
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Introduction 
 
AKU is caused by deficiency of homogentisate 1,2-dioxygenase (HGD). 
HGD converts homogentisic acid (HGA) to maleylacetoacetic acid in the tyro-
sine degradation pathway [1]. Darkening of the urine upon standing is a striking 
sign of the disease. The phenomenon is caused by the oxidation of the HGA 
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excreted in the urine. The bluish-black pigmentation in connective tissue (ochro-
nosis) usually occurs after the age of 30 years [2]. Clinically important arthritis 
begins in the third decade and after several decades can be disabling [3]. Rare 
phenomena are aortic or mitral valve calcification or regurgitation [4], renal and 
prostate stones. AKU patients excrete a significant amount of HGA in the urine.  
Ocular ochronosis is rarely seen in children [5, 6]. Inpeed, the ocular 
ochronosis and dark urine prompted the diagnosis of AKU in a 14year-old 
Macedonian girl.  
 
 
Case report 
 
The patient’s parents reported staining of urine from the age of 5 
months with the urine actually darkening to blackness on standing. The proband 
is the second child in a family of young and healty parents. Her mental and 
physical development is normal. She is a nice-looking, excellent stdent in high-
school. No degenerative joint disease was noted until the age of 14 years. On 
ophthalmological examination, the patient revealed bilateral grey brown of the 
temporal sclera. Discoloration of the ears and an irregular thickening of auricu-
lar cartilage were not observed. 
Elevated excretion of homogentisic acid in urine was found in the 
proband, but not in the other members of the family. HGD gene sequencing 
from genomic DNA revealed that the proband is a compound heterozygote with 
a previously described mutation p.Pro158Leu (c.473C > T) in exon 8), and 
a novel one p.Pro274Leu (c.821C > T) affecting exon 11 (Fig. 1). As can be 
seen in Fig. 1, her mother is heterozygous for the same novel mutation and her 
brother is heterozygous for the mutation in exon 8. The father’s DNA was not 
available for analysis. Both mutations have also been submitted to the novel 
HGD mutation database under the family code AKU_DB_116. 
 
 
Discussion 
 
This patient is the first diagnosed and published AKU in Macedonia. So 
far, about 250 cases of alkaptonuria have been reported in whom HGD mutations 
have also been identified (HGD mutation database; http://hgddatabase.cvtisr.sk/, 
[1, 7]. Worldwide, AKU has a low prevalence of 1 : 250 000 (USA 1 : 250,000 
– 1 : 1,000,000 live births). The notable exeptions are Slovakia (1 : 19 000) [8, 
9, 10] and the Dominican Republic [11, 12]. It is of historical interest that AKU 
is the first human disease to be understood as a recessive trait [13]. 
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Fig. 1 – Schematic representation of the pedigree and the mutations identified. The 
proband is a compound heterozygote with a previously described mutation p.Pro158Leu 
(c.473C > T)( in exon 8 ) (black arrow), and a novel one p.Pro274Leu (c.821C > T) 
affecting exon 11 (red arrow). The mother is heterozygous for the same novel mutation 
in exon 11 and her brother is heterozygous for the mutation in exon 8 
  
Dark urine or urine that turns dark on standing or exposure to an alka-
line agent, ochronosis (bluish-black pigmentation of connective tissue: accumu-
lation of HGA and its oxidation products), and arthritis are AKU’s main cha-
racteristics.  
Arthritis often begins in the spine and resembles ankylosing spondylitis 
in its large-joint distribution [3]. Fifty percent of individuals require at least one 
joint replacement by the age of 55 years [2, 14]. 
The ear cartilage can be slate blue or gray and thickened. Cerumen in 
perspiration can also be coloured and can cause discoloration of clothing.  
Ocular ochronosis is a brown pigmentation of the sclera between the 
cornea and the outer and inner canthi. It may affect the conjunctiva and cornea, 
too [5]. Furthermore, ocular ochronosis usually precedes the appearance of arti-
cular symptoms [6]. It is of note that the differential diagnosis of blue black 
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scleral pigmentation includes malignant melanoma of the choroid and that this 
diagnosis can be missed [15]. 
Urolithiasis has been described in adults and in children with AKU e.g. 
[2, 16, 17]. Intellectual capacity and life expectancy are not reduced in AKU. 
The diagnosis of alkaptonuria is based on the detection of a significant 
amount of HGA in the urine by gas chromatography-mass spectrometry analy-
sis [1, 2]. However, biochemical testing cannot detect the heterozygotes.  
The majority of the ~ 91 HGD mutations reported so far are missense 
[16]. Nonsense, frame shift, and splice-site mutations have been described. Some 
populations show a founder effect for the frequent mutations, such as p.Gly161Arg 
mutation in Slovakia [9] or p.Cys120Trp in the Dominican Republic [12]. The most 
prevalent mutation in Europe is p.Met368Val, while in the US, no mutational hot 
spot or founder effect has been identified [2]. So far no correlation has been obser-
ved between the type of HGD mutation and amount of HGA excreted or severity of 
the disease. More detailed and extended studies in larger groups of patients are 
necessary to follow possible genotype- phenotype correlations. 
Mutation p.Pro158Leu, found in our patient, was previusly reported in a 
patient from the USA who carried mutation p. Ser59AlafsX52 (c174_175delA) 
in exon 3 on his second allele [16]. Intrestingly, mutation p.Pro158Leu affects 
nucleotide c.473C that has already also been found mutated into G in another 
case from USA, causing amminoacid change p.Pro158Arg [2]. 
Novel mutation p.Pro274Leu affects nucleotide c.821C that is highly 
conserved in Homo sapiens, Mus musculus, Rattus norvegicus, Danio rerio, Dro-
sophila melanogaster, Arabinopsis thaliana and Aspergillus nidulans (ClustalW2, 
data not shown). In addition, PolyPhen-2 (Polymorphism Phenotyping v2) (21) 
and SNAP (Screening for non-acceptable polymorphisms) [22] programmes were 
used to predict an impact of this amino acid substitution on the structure and 
function of a human HGD protein (NP_000178.2). Both programmes predicted a 
probably damaging effect, further confirming the pathogenity of this novel HGD 
mutation.  
No correlation is observed between the type of HGD mutation and amount 
of HGA excreted or severity of the disease. 
So far, no effective preventive or curative treatment for AKU is avai-
lable. Nitisinone is not approved in the treatment of AKU.[19] Severe restrict-
tion of phenylalanine and tyrosine may be dangerous. No studies have demon-
strated the clinical efficacy of ascorbic acid [1]. A prospective study with oral 
bisphosphonate therapy did not demonstrate benefit [20].  
This is the first Macedonian patient with AKU. A novel mutation has 
been described as well as an unusualy early ocular ochronosis.  
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Алкаптонуријата е нарушување на метаболизмот на фенилаланин/тирозин 
како резултат на дефект во ензимот хомогентизат 1,2-диоксигеназа (ХГД). Ова 
рецесивно нарушување е предизвикано од мутации во ХГД генот. Ние прикажуваме 
14-годишно девојче примено заради појава на црна урина. Деталните иследувања 
утврдија постоење на конјуктивална охроноза, но без афекција на срцевите залистоци. 
Беше најдено зголемена екскреција на хомогентизинска киселина во урината. Секвен-
ционата анализа на ХГД генот покажа дека пациентот е хетерозигот со претходно 
опишана мутација (c.473C > T, p.Pro158Leu) и една нова мутација (c.821C > T, 
p.Pro274Leu). Мајката и братот се исто така хетерозиготи за новата мутација. ДНК од 
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таткото не беше достапна за анализа. Како заклучок, опишуваме пациент со алкапто-
нурија со очна охроноза и нова ХГД мутација c.821C > T, p.Pro274Leu. 
 
Клучни зборови: алкаптонурија, нова мутација, окуларна охроноза. 
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